NCT05176379View on ClinicalTrials.gov

Endothelial Derived Hyperpolarization Factor and Vascular Control

PHASE4RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 19, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

May 31, 2025

Conditions
Healthy
Interventions
DRUG

Fluconazole 150 mg

A single acute 150 mg dose

Trial Locations (1)

73019

RECRUITING

Department of Health and Exercise Science, Norman

All Listed Sponsors
lead

University of Oklahoma

OTHER

NCT05176379 - Endothelial Derived Hyperpolarization Factor and Vascular Control | Biotech Hunter | Biotech Hunter